Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.
about
Mechanisms of amino acid-stimulated insulin secretion in congenital hyperinsulinismGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesMechanism of hyperinsulinism in short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency involves activation of glutamate dehydrogenaseDiazoxide-unresponsive congenital hyperinsulinism in children with dominant mutations of the β-cell sulfonylurea receptor SUR1Targeting SUR1/Abcc8-type neuroendocrine KATP channels in pancreatic islet cells.Repair of diverse diabetic defects of β-cells in man and mouse by pharmacological glucokinase activationA liquid chromatography-mass spectrometry assay for quantification of Exendin[9-39] in human plasma.Dipeptidyl peptidase-4 expression in pancreatic tissue from patients with congenital hyperinsulinismRegulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides.GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channelRegulation of glucagon secretion in normal and diabetic human islets by γ-hydroxybutyrate and glycine.Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism DisordersCongenital hyperinsulinism: current trends in diagnosis and therapy.In vitro insulin secretion by pancreatic tissue from infants with diazoxide-resistant congenital hyperinsulinism deviates from model predictions.Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties.A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.Diagnosis and treatment of hyperinsulinaemic hypoglycaemia and its implications for paediatric endocrinology.Congenital Hypoglycemia Disorders: New Aspects of Etiology, Diagnosis, Treatment and Outcomes: Highlights of the Proceedings of the Congenital Hypoglycemia Disorders Symposium, Philadelphia April 2016.Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret.Activation of intestinal olfactory receptor stimulates glucagon-like peptide-1 secretion in enteroendocrine cells and attenuates hyperglycemia in type 2 diabetic mice.Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.Congenital Hyperinsulinism: Diagnosis and Treatment Update.Chronic β-Cell Depolarization Impairs β-Cell Identity by Disrupting a Network of Ca2+-Regulated Genes.Nutrient sensing in pancreatic islets: lessons from congenital hyperinsulinism and monogenic diabetes.The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.A unique allosteric insulin receptor monoclonal antibody that prevents hypoglycemia in the SUR-1(/( mouse model of KATP hyperinsulinism.Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
P2860
Q27015645-E2CCA684-387A-4A94-99E1-A0C4F70CD725Q28067465-2D2A6888-ED99-4706-AD52-7AA8113AE0F9Q34181596-85234F1A-8600-49F3-A1E5-628476B3C53AQ35043418-FAF8D081-9CD1-4EA3-8681-A75CAB49E3A3Q35118797-A55423A5-8EBB-4400-8A46-48FA54EA3389Q35611074-5687A332-F675-44D9-8648-9F734FEE58F7Q35898828-0FC51385-A1C1-4162-8CC9-A5DC9C8ACB0FQ36014334-564CB94C-AAE2-4814-925E-810F21B2228CQ36049852-05F5A7C4-D857-4E1D-AE29-8F1DBEAD8DDAQ36249759-3AE2870D-CA30-47C1-8977-D66A0A976A12Q36596183-D2D430E0-642B-415A-8EAD-921D57051561Q36716020-E3A9F695-E5C2-4329-AAE8-2EDADC63190AQ37941900-5FCDDB42-89AF-48D6-9F74-D2EC3F30CB83Q38732653-C35E3E99-6059-4989-ADCA-2A72B8FC0E38Q39401763-C1D01D0C-5CCD-4A79-885B-4397AD2D447BQ39544576-135DBA09-E34A-4A69-AE3C-D01FF0C5F267Q41555063-0DD42435-009E-4707-B388-A71C06F9FA28Q41809055-7F8202ED-C4DA-4FD3-A971-62BB6896388CQ41949833-2CC25D6B-D7C9-4260-A726-C333DC723C4AQ42630113-3E287488-BC0D-4568-97EA-113C882DED92Q47872785-37FC37B8-4BE6-45A6-841D-793D8B403A17Q47894084-D1BC6A46-77DD-4C6A-9E60-FC12C7AC0396Q48368514-FC80DE6A-6518-4AEC-815D-08705426F0C5Q50088043-68145E44-2CAA-4EA1-9D4A-A2DD5D3B005DQ50994560-F63CCE27-8902-4FAF-B8E0-B0454C9D7AC1Q51244136-CF749592-DD88-493B-82E9-AF65E9142712Q51621034-6641AAD3-2EB8-46CA-A168-5405CE76AA31
P2860
Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Exendin-(9-39) corrects fastin ...... inhibiting insulin secretion.
@en
type
label
Exendin-(9-39) corrects fastin ...... inhibiting insulin secretion.
@en
prefLabel
Exendin-(9-39) corrects fastin ...... inhibiting insulin secretion.
@en
P2093
P2860
P356
P1476
Exendin-(9-39) corrects fastin ...... inhibiting insulin secretion.
@en
P2093
Changhong Li
Diva D De León
Doris A Stoffers
Franz M Matschinsky
Madeleine I Delson
P2860
P304
25786-25793
P356
10.1074/JBC.M804372200
P407
P577
2008-07-17T00:00:00Z